| Date |
Subject |
Media |
| 2025-08-28 |
New Drug Licensing to Bear Fruit in Q4: AP Biosciences, Oneness Biotech, and TAHO Pharmaceuticals Gain International Attention
|
Taiwan’s new drug licensing momentum is accelerating, with several companies expected to see results next quarter. The biotech sector has recently attracted significant capital inflows, with companies such as OBI Pharma’s AP Biosciences, MICROBIO Group’s Oneness Biotech, and TAHO Pharmaceuticals gaining attention as their pipeline products move closer to licensing milestones, with positive developments anticipated in the coming quarter. |
| 2025-08-28 |
ALA-1000 to Enter Phase III in Q1 Next Year, Alar Pharmaceuticals Poised for New Milestone Payments
|
Alar Pharmaceuticals’ licensing partner Indivior reported second-quarter revenue and profit that exceeded expectations, which industry observers interpret as validation of its new management team’s focus on addiction-treatment drugs. This also means more resources are available to advance ALA-1000 (INDV-6001) into a Phase III clinical trial, set to begin no later than the first quarter of 2026. With trial enrollment underway, Alar is expected to receive a new wave of milestone payments, boosting profitability. |
| 2025-08-28 |
MegaPro Biomedical’s Dual Technology Platforms Drive Progress, Two Products Targeting NDA Filings by 2028
|
MegaPro Biomedical announced on the 5th that its dual technology platforms are gaining momentum. The company plans to submit a Pre-IND application for its MRI contrast agent MPB-1523 by the end of this year, paving the way for a formal 505(b)(1) NDA submission in 2028. At the same time, its reformulated oncology drug MPB-1734 will advance to bioequivalence testing following successful process scale-up, with a 505(b)(2) NDA submission also expected in 2028. |
| 2025-08-28 |
New Leadership at NTU Hospital Hsinchu Branch: Kuan-Yu Hung Returns as Superintendent, While Chong-Jen Yu Takes the Helm of the Main Hospital
|
On the afternoon of the 1st, the Hsinchu Branch of National Taiwan University Hospital (NTUH) held a handover ceremony at its Zhubei campus. The event was personally overseen by Ming-Shiang Wu, Dean of the NTU College of Medicine. During the ceremony, newly appointed NTUH Superintendent Chong-Jen Yu formally passed the seal of office to Kuan-Yu Hung, officially completing the transition. |
| 2025-08-28 |
Anbogen Therapeutics Reaches New Milestone: FDA Clears ABT-301 Triple Combination Therapy Targeting Advanced Colorectal Cancer “Cold Tumors”
|
Anbogen Therapeutics (ABT), a precision medicine biotech company, announced a major breakthrough today with the U.S. FDA’s approval to initiate Phase I/II clinical trials for its small-molecule drug ABT-301, in combination with an immune checkpoint inhibitor and an anti-angiogenic inhibitor. This triple-combination therapy will target advanced metastatic colorectal cancer (mCRC), particularly “cold tumors” that account for 90% of patients who respond poorly to current immunotherapies, offering renewed hope for this underserved population. |
| 2025-08-28 |
Taiwan Bio Therapeutics: Phase II Osteoarthritis Trial Meets Secondary Endpoint, Paving Way to Accelerate Phase III
|
Cell therapy developer Taiwan Bio Therapeutics announced results from its Phase IIb clinical trial for osteoarthritis (OA). While the primary pain reduction endpoint did not show statistically significant improvement compared to the hyaluronic acid control group, the study revealed notable efficacy in secondary endpoints, particularly in joint structure improvement—a result rarely seen among competing products. This outcome has become a major highlight, and the company now intends, together with its Singapore licensing partner, to accelerate the launch of Phase III trials, aiming to begin patient enrollment both domestically and internationally by the end of this year, though overseas enrollment may be slightly lower than initially projected. |
| 2025-08-27 |
Healthy Ageing Tech Show to Open on August 8
|
Targeting the trillion-dollar global silver economy, the “2025 Healthy Ageing Tech Show,” co-hosted by the Institute for Biotechnology and Medicine Industry (IBMI), the Research Center for Biotechnology and Medicine Policy, the Department of Industrial Development (DID), Ministry of Economic Affairs (MOEA), and the National Health Research Institutes (NHRI), will take place from August 8 to 10. This year’s event brings together 350 leading exhibitors across 1,200 booths, setting a new record in scale. |
| 2025-08-27 |
Silver Economy Emerging as New Blue Ocean: Top 10 Senior-Friendly Innovative Technologies Announced
|
As Taiwan enters a super-aged society, the silver economy is booming with unprecedented business opportunities. The latest selection of the “Top 10 Senior-Friendly Technology Products” has been unveiled, highlighting innovative solutions such as National Taiwan University Hospital Yunlin Branch’s Smart Indoor Positioning System, UGYM Technology’s Pain Relief Electrotherapy Device, imedtac’s Automated Bathing Machine, and CTBC Bank’s Senior-Friendly ATM with AI-powered fraud prevention. Industry experts believe these innovations not only showcase Taiwan’s strong R&D capabilities but also demonstrate international competitiveness, serving as important indicators for investment and industrial transformation. |
| 2025-08-27 |
Formosa Biomedical Technology and Rohto Pharmaceutical Sign Strategic Partnership to Expand Regenerative Medicine Market in Taiwan and Japan
|
Formosa Biomedical Technology announced on August 1 that, on behalf of Formosa Plastics Group’s regenerative medicine ecosystem—including IVY LIFE SCIENCE—the company signed a strategic partnership agreement with Japan’s globally renowned Rohto Pharmaceutical Co., Ltd. on July 22, marking the beginning of a deep collaboration in regenerative medicine between Taiwan and Japan. |
| 2025-08-27 |
Protect Animal Health Incorporation to Debut on Emerging Stock Board August 4 at NT$33 per Share, Targeting the Billion-Dollar Senior Pet Medicine Market
|
Protect Animal Health Incorporation, an innovative veterinary drug developer, is set to debut on Taiwan’s Emerging Stock Board on August 4 with a broker-underwritten reference price of NT$33 per share. Leveraging its “Moneyball Strategy,” platform-based incubation capabilities, and global partnerships, Protect is advancing three high-value therapeutic areas: cancer immunotherapy vaccines, gene therapy for heart disease, and an antibody drug platform. Together, these markets are valued at nearly NT$20 billion (approximately US$660 million). Its lead candidate, PT001, a novel melanoma vaccine, has already filed for field trials and will first be developed in Taiwan before expanding to global markets. |
